Featured Cores

UNC CFAR has seven Cores each of which offer unique services to support the entire spectrum of HIV/AIDS research. For the complete list of UNC CFAR Cores, follow the "View All" below.

View All

Administrative Core

The Administrative Core supports and promotes the entire range of basic, clinical, prevention, social, behavioral, and translational HIV research activities throughout the UNC CFAR.

Biostatistics Core

The purpose of the CFAR Biostatistics Core is to accelerate successful HIV/AIDS research by direct provision of biostatistical support and by arranging mutually beneficial collaborations between CFAR researchers and statistical scientists.

Clinical Core

The goal of the Clinical Core (Core C) is to facilitate and enhance clinical and translational HIV/AIDS research at UNC, FHI and RTI.

UNC CFAR in the News

Innovations in HIV Research

New book: Innovations in HIV Prevention Research and Practice through Community Engagement

UNC CFAR investigator Scott Rhodes, PhD, MPH, from the Wake Forest School of Medicine has edited a new book: Innovations in HIV Prevention Research and Practice through Community Engagement. Leaders in the field who are working at various points along the community-engagement continuum, with diverse populations, and different types of HIV prevention interventions (e.g., individual, community, and… Read More

Dr. Myron Cohen

Cohen to deliver 2014 Norma Berryhill Distinguished Lecture

CFAR Associate Director Dr. Myron Cohen (Associate Vice Chancellor for Global Health; Yeargan-Bate Eminent Distinguished Professor of Medicine, Microbiology and Immunology, and Epidemiology; and Chief, Division of Infectious Diseases and Director, Institute for Global Health & Infectious Diseases) will deliver the 2014 Norma Berryhill Distinguished Lecture. The event will be held Wednesday, October 22, at… Read More

Katie Mollan, MS

UNC CFAR in the News: HIV drug linked to higher suicide risk

The UNC CFAR is getting exciting news coverage! Our researchers Katie Mollan, MS, Joe Eron, MD, Kevin Robertson, MD, and ACTG investigators have been featured in WedMD, Harvard News, and MedPage Today for their new article which explores the risks of anti-HIV drug efavirenz. This drug appears to double the risk that patients will develop… Read More